In vivo and in vitro pharmacological studies of methoxycarbonyl- carboetomidate

Anesthesia and Analgesia

Volumn 115, Issue 2, 2012, Pages 297-304

  Pejo, Ervin ^a   Cotten, Joseph F ^a   Kelly, Elizabeth W ^a   Le Ge, Ri ^a   Cuny, Gregory D ^b   Laha, Joydev K ^b   Liu, Jifeng ^c   Jie Lin, Xiang ^c   Raines, Douglas E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Aberjona Laboratories Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ANESTHETIC AGENT; ETOMIDATE; METHOXYCARBONYL CARBOETOMIDATE; OCTANOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; HEMODYNAMICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; VOLTAGE CLAMP;

ADRENAL CORTEX; ANIMALS; BLOOD PRESSURE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG STABILITY; ETOMIDATE; GABA-A RECEPTOR AGONISTS; HYPNOTICS AND SEDATIVES; LARVA; MALE; MEMBRANE POTENTIALS; MOLECULAR STRUCTURE; OCTANOLS; PATCH-CLAMP TECHNIQUES; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GABA-A; REFLEX; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS; WATER; XENOPUS LAEVIS;

EID: 84864414890     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e3182320559     Document Type: Article

References (23)

1. Janssen PA, Niemegeers CJ, Schellekens KH, Lenaerts FM. Etomidate, R-(+)-ethyl-1-(-methyl-benzyl)imidazole-5-carboxylate (R 16659), a potent, short-acting and relatively atoxic intravenous hypnotic agent in rats. Arzneimittelforschung 1971;21:1234-43
2. Vinson DR, Bradbury DR. Etomidate for procedural sedation in emergency medicine. Ann Emerg Med 2002;39:592-8 (Pubitemid 34596051)
3. Guldner G, Schultz J, Sexton P, Fortner C, Richmond M. Etomidate for rapid-sequence intubation in young children: hemodynamic effects and adverse events. Acad Emerg Med 2003;10:134-9 (Pubitemid 36262572)
4. Zed PJ, Abu-Laban RB, Harrison DW. Intubating conditions and hemodynamic effects of etomidate for rapid sequence intubation in the emergency department: an observational cohort study. Acad Emerg Med 2006;13:378-83
5. Dhawan N, Chauhan S, Kothari SS, Kiran U, Das S, Makhija N. Hemodynamic responses to etomidate in pediatric patients with congenital cardiac shunt lesions. J Cardiothorac Vasc Anesth 2010;24:802-7
6. Siedy J, Knapik P, Saucha W, Gross M. Comparison of propofol and etomidate anaesthesia for elective electrical cardioversion. Kardiol Pol 2010;68:1249-55
7. de Jong FH, Mallios C, Jansen C, Scheck PA, Lamberts SW. Etomidate suppresses adrenocortical function by inhibition of 11 beta-hydroxylation. J Clin Endocrinol Metab 1984;59:1143-7 (Pubitemid 15223350)
8. Wagner RL, White PF, Kan PB, Rosenthal MH, Feldman D. Inhibition of adrenal steroidogenesis by the anesthetic etomidate. N Engl J Med 1984;310:1415-21 (Pubitemid 14101296)
9. Duthie DJ, Fraser R, Nimmo WS. Effect of induction of anaesthesia with etomidate on corticosteroid synthesis in man. Br J Anaesth 1985;57:156-9 (Pubitemid 15093403)
10. Jackson WL, Jr. Should we use etomidate as an induction agent for endotracheal intubation in patients with septic shock?: a critical appraisal. Chest 2005;127:1031-8 (Pubitemid 40775537)
11. Fengler BT. Should etomidate be used for rapid-sequence intubation induction in critically ill septic patients? Am J Emerg Med 2008;26:229-32 (Pubitemid 351215769)
12. Hildreth AN, Mejia VA, Maxwell RA, Smith PW, Dart BW, Barker DE. Adrenal suppression following a single dose of etomidate for rapid sequence induction: a prospective randomized study. J Trauma 2008;65:573-9
13. Cuthbertson BH, Sprung CL, Annane D, Chevret S, Garfield M, Goodman S, Laterre PF, Vincent JL, Freivogel K, Reinhart K, Singer M, Payen D, Weiss YG. The effects of etomidate on adrenal responsiveness and mortality in patients with septic shock. Intensive Care Med 2009;35;1868-76
14. Kulstad EB, Kalimullah EA, Tekwani KL, Courtney DM. Etomidate as an induction agent in septic patients: red flags or false alarms? West J Emerg Med 2010;11:161-72
15. Cotten JF, Husain SS, Forman SA, Miller KW, Kelly EW, Nguyen HH, Raines DE. Methoxycarbonyl-etomidate: a novel rapidly metabolized and ultra-short-acting etomidate analogue that does not produce prolonged adrenocortical suppression. Anesthesiology 2009;111:240-9
16. Cotten JF, Forman SA, Laha JK, Cuny GD, Husain SS, Miller KW, Nguyen HH, Kelly EW, Stewart D, Liu A, Raines DE. Carboetomidate: a pyrrole analog of etomidate designed not to suppress adrenocortical function. Anesthesiology 2010;112: 637-44
17. Waud DR. On biological assays involving quantal responses. J Pharmacol Exp Ther 1972;183:577-607
18. Rusch D, Zhong H, Forman SA. Gating allosterism at A single class of etomidate sites on alpha1beta2gamma2l GABA A receptors accounts for both direct activation and agonist modulation. J Biol Chem 2004;279:20982-92 (Pubitemid 38656498)
19. Quon CY, Stampfli HF. Biochemical properties of blood es-molol esterase. Drug Metab Dispos 1985;13:420-4
20. Shafer SL Principles of Pharmacokinetics and Pharmacody-namics. In: Longnecker DE, Tinker JH, Morgan GE, eds. Anesthesiology. St. Louis: Mosby, 1998:1159-210
21. Liao M, Sonner JM, Husain SS, Miller KW, Jurd R, Rudolph U, Eger EI, 2nd. R (+) etomidate and the photoactivable R (+) azietomidate have comparable anesthetic activity in wild-type mice and comparably decreased activity in mice with a N265M point mutation in the gamma-aminobutyric acid receptor beta3 subunit. Anesth Analg 2005;101:131-5 (Pubitemid 40853363)
22. Dutta S, Ebling WF. Emulsion formulation reduces propofol's dose requirements and enhances safety. Anesthesiology 1997;87:1394-405 (Pubitemid 28007336)
23. Dutta S, Ebling WF. Formulation-dependent brain and lung distribution kinetics of propofol in rats. Anesthesiology 1998;89:678-85 (Pubitemid 28423966)